Board of Directors

Dr. Frank Kalkbrenner

Frank Kalkbrenner is Managing Director of the Boehringer Ingelheim (BI) Venture Fund, the lead investor in Acousia. He has extensive experience in Drug Discovery and Development as well as in licensing and business development. Before joining the venture fund in 2010 Frank Kalkbrenner headed the German licensing organization of BI. Frank Kalkbrenner received his MD from the University of Berlin and did his post-doc research in the Max-Planck-Institute in Berlin before he trained in Pharmacology and Toxicology. Before moving to licensing he held several position in Research in Inflammatory and Pulmonary diseases at Schering AG and BI.


Prof. Dr. Hubert Löwenheim

Hubert Löwenheim is Medical Director of the ENT University Clinic in Tübingen and Principal Investigator of “Regenerative Biology Group”. He has extensive experience in the field of regenerative hearing loss therapies both scientifically and clinically. He was the first describing the involvement of cell cycle regulators esp. p27Kip1 in the proliferation and differentiation of hair cells and supporting cells in the cochlea. In 1998, based on these discoveries he co-founded the company Otogene AG in Tübingen and its subsidiary Otogene Inc. in Seattle with the aim to identify an inhibitor of p27Kip1 as regenerative drug. Hubert Löwenheim received his MD from Goethe University, Frankfurt am Main and trained in Otorhinolaryngology at the University of Tübingen. His doctoral degree from Goethe University is in auditory physiology, his Habilitation degree from Tübingen University is in auditory regenerative biology. His clinical focus is in Otology & Neurootology. He has published over 50 scientific articles in the area of hearing research.


Dr. Stefan Lohmer

Stefan Lohmer is the President, Chief Executive Officer and Founder of Axxam S.p.A. (Milan). Since its inception in 2001, he has positioned Axxam as an innovator for the identification of bioactive small molecules applying high throughput screening for membrane proteins like GPCRs, Transporters and Ion Channels. Nearly all of the company’s discovery projects are focused on neuroinflammation and neurodegeneration. Dr. Lohmer brings more than 25 years of experience in the field of small molecule drug discovery. Prior to founding Axxam, he held various positions with increasing seniority at Bayer Pharmaceuticals, culminating in the World Wide Head of Genomics. Dr. Lohmer holds a PhD in Molecular Biology and Genetics from the Albertus Magnus University Koeln, Germany.  He is an inventor on several patents and has authored 20 peer-reviewed publications.